{"id":"NCT02402933","sponsor":"Eli Lilly and Company","briefTitle":"Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents","officialTitle":"A Multiple Center, Open Label, Prospective Study to Evaluate the Effectiveness and Ease-Of-Use of AMG504-1 Administered in the Home or School Environments for Treating Hypoglycemia in Children and Adolescents With T1D","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03","primaryCompletion":"2015-08","completion":"2015-08","firstPosted":"2015-03-30","resultsPosted":"2017-06-26","lastUpdate":"2019-09-23"},"enrollment":26,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypoglycemia","Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Nasal Glucagon","otherNames":["Dry-Mist nasal glucagon","AMG504-1","LY900018"]}],"arms":[{"label":"Nasal Glucagon","type":"EXPERIMENTAL"}],"summary":"Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to Ë‚18 years at time of enrolment will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of Nasal Glucagon (LY900018) in treating episodes of hypoglycemia.","primaryOutcome":{"measure":"Number of Participants Awakening or Returning to a Normal Status Within 30 Minutes Following Studied Drug of Administration","timeFrame":"Within 30 minutes after each drug administration for an episode of hypoglycemia","effectByArm":[{"arm":"Nasal Glucagon","deltaMin":14,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":8},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["Nasal Discomfort","Watery Eyes","Headache","Nausea","Abdominal Pain Upper"]}}